Adagene Inc. (ADAG): Price and Financial Metrics
ADAG Price/Volume Stats
| Current price | $2.51 | 52-week high | $4.38 |
| Prev. close | $2.64 | 52-week low | $1.10 |
| Day low | $2.51 | Volume | 1,810 |
| Day high | $2.63 | Avg. volume | 93,012 |
| 50-day MA | $2.99 | Dividend yield | N/A |
| 200-day MA | $2.05 | Market Cap | 110.73M |
ADAG Stock Price Chart Interactive Chart >
Adagene Inc. (ADAG) Company Bio
Adagene Inc. operates as a biotechnology company. The Company focuses on the development of antibodies to cancer patients. Adagene serves patients in the United States and China.
Latest ADAG News From Around the Web
Below are the latest news stories about ADAGENE INC that investors may wish to consider to help them evaluate ADAG as an investment opportunity.
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023- MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab – - Integrated pharmacokinetic and clinical data analyses support the mechanism of action for ADG126 and its profile as a potential best-in-class CTLA-4 therapy across tumor types - SAN DIEGO and SUZHOU, China, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the disco |
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?Here is how Boston Scientific (BSX) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year. |
Are Medical Stocks Lagging Medpace (MEDP) This Year?Here is how Medpace (MEDP) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year. |
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting- Data reinforces mechanism of action and selection of 10 mg/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort – SAN DIEGO and SUZHOU, China, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its poster presentation at the SITC 38th Annual Meeting taking place November 1-5, 2023 in San Diego. Details for the poster i |
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?Here is how Adagene Inc. Sponsored ADR (ADAG) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year. |
ADAG Price Returns
| 1-mo | -11.93% |
| 3-mo | -4.92% |
| 6-mo | 79.29% |
| 1-year | 69.59% |
| 3-year | -81.41% |
| 5-year | N/A |
| YTD | 29.96% |
| 2023 | 45.77% |
| 2022 | -83.58% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...